Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.
On February 4, 2026, CEO John Marotta told investors Azenta was “entering the year well positioned for continued success” and reaffirmed FY 2026 guidance of 3%-5% organic revenue growth with approximately 300 basis points of adjusted EBITDA margin expansion. On May 5, 2026, the Company reported Q2 FY 2026 results that included a $149 million goodwill impairment charge in its Multiomics segment. The resulting net loss of $160.8 million stood in stark contrast to the growth trajectory management had presented ninety days prior.
Alongside the impairment, Azenta reduced its full-year FY 2026 guidance — trimming the revenue growth and margin expansion targets it had publicly reaffirmed in February. The gap between the Company’s stated outlook and its reported results is now the subject of an investigation into potential securities law violations.